From real-world data to digital therapeutics, this MVP Technology Framework evaluates the tech solutions pharmaceutical companies and contract research organizations (CROs) like Pfizer and IQVIA are using to develop and deliver personalized medicine.
Pharmaceutical companies and CROs are investing in technologies that improve the likelihood of prescribing the right drug to the right patient at the right time. From synthetic data to genomic profiling, new tech-driven tools are offering significant improvements in the field of precision medicine.
Key trends to watch in the space include:
- Digital therapeutics: These software-driven, evidence-based therapies are gaining traction as viable solutions to help manage mental health, diabetes, and more.
- Real-world data use cases: Alternative datasets — gathered from sources such as patient registries, EHRs, and insurance databases — are being used to supplement clinical trial outcomes, personalize treatment, and create “digital twins” of patients.
- Patient-specific therapy: Advances in genomic sequencing and molecular diagnostics are enabling pharmaceutical companies and providers to develop and deliver therapies with higher probabilities of success.
This report evaluates 9 precision medicine tech markets that pharmaceutical and CRO leaders should monitor, vet, and prioritize.
Want the full expert post? Become a CB Insights customer. If you’re already a customer, log in here.